高危乳腺癌辅助化疗后乳房切除术后放疗的时机:一项随机对照临床试验的事后分析
该事后分析纳入一项随机对照临床试验中584例II期和III期乳腺癌患者,均行乳房切除术后序贯化疗和放疗。中位随访83.5个月,手术-放疗间隔(SRI)>210天与更差的总生存(OS)、无病生存(DFS)和更高远处转移(DM)独立相关;化疗-放疗间隔(CRI)>42天亦与更差OS、DFS和更高DM独立相关;SRI和CRI对局部区域复发(LRR)无显著影响。
要点
- SRI>210天者DM风险更高(HR 2.65,95%CI 1.49-4.71;HR 2.78,95%CI 1.51-5.26),OS更差(HR 2.44,95%CI 1.28-4.54;HR 2.50,95%CI 1.41-4.35),DFS更差(HR 2.57,95%CI 1.45-4.57;HR 2.70,95%CI 1.45-5.00)。
- CRI>42天者DM风险更高(HR 1.89,95%CI 1.17-3.06;HR 1.96,95%CI 1.19-3.22),OS更差(HR 2.44,95%CI 1.41-4.35;HR 1.92,95%CI 1.10-3.33),DFS更差(HR 1.84,95%CI 1.14-2.96;HR 1.82,95%CI 1.12-2.94)。
- SRI和CRI对LRR无显著影响。
核心结论
- 基于本研究发现,高危乳腺癌患者乳房切除术后及辅助化疗完成后开始放疗的时机均至关重要。
研究设计与样本
- 对一项随机对照临床试验中584例II期和III期乳腺癌患者进行事后分析。
- 所有患者均接受乳房切除术,随后序贯化疗和放疗。
- 采用连续预测变量的风险比确定手术-放疗间隔(SRI)和化疗-放疗间隔(CRI)对总生存(OS)的最佳截断值。
- 采用Kaplan-Meier法估计局部区域复发(LRR)、远处转移(DM)、无病生存(DFS)和OS率。
- 采用Cox比例风险回归进行多因素分析。
主要发现
- 中位随访时间为83.5个月;中位SRI为168天,中位CRI为27天。
- SRI>210天与SRI<180天或180-210天相比,DM风险更高(HR 2.65,95%CI 1.49-4.71;HR 2.78,95%CI 1.51-5.26),OS更差(HR 2.44,95%CI 1.28-4.54;HR 2.50,95%CI 1.41-4.35),DFS更差(HR 2.57,95%CI 1.45-4.57;HR 2.70,95%CI 1.45-5.00)。
- CRI>42天与CRI<28天或28-42天相比,DM风险更高(HR 1.89,95%CI 1.17-3.06;HR 1.96,95%CI 1.19-3.22),OS更差(HR 2.44,95%CI 1.41-4.35;HR 1.92,95%CI 1.10-3.33),DFS更差(HR 1.84,95%CI 1.14-2.96;HR 1.82,95%CI 1.12-2.94)。
- SRI和CRI对LRR无显著影响。
关键数值与推荐
- SRI最佳截断值为210天;SRI>210天与更差DM、OS和DFS独立相关(HR见主要发现)。
- CRI最佳截断值为42天;CRI>42天与更差DM、OS和DFS独立相关(HR见主要发现)。
- SRI分组比较:>210天 vs <180天或180-210天。
- CRI分组比较:>42天 vs <28天或28-42天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the appropriate timing of radiotherapy (RT) after mastectomy and adjuvant chemotherapy for women with high-risk breast cancer. PATIENTS AND METHODS: Post hoc analyses of 584 patients with stage II and III breast cancer from a randomised controlled clinical trial were performed. All patients underwent mastectomy followed by sequential chemotherapy and RT. The optimal cut-off values for the surgery-RT interval (SRI) and the chemotherapy-RT interval (CRI) for overall survival (OS) were determined using the hazard ratio for continuous predictors. The locoregional recurrence (LRR), distant metastasis (DM), disease-free survival (DFS), and OS rates were estimated using the Kaplan-Meier method. Multivariate analyses were performed using Cox proportional hazards regression. RESULTS: Median follow-up time was 83.5 months. Median SRI and CRI were 168 and 27 days, respectively. An SRI of >210 days was independently associated with higher DM (HR 2.65, 95% CI: 1.49-4.71; HR 2.78, 95% CI 1.51-5.26), lower OS (HR 2.44, 95% CI: 1.28-4.54; HR 2.50, 95% CI: 1.41-4.35), and lower DFS (HR 2.57, 95% CI: 1.45-4.57; HR 2.70, 95% CI: 1.45-5.00) than SRI of <180 or 180-210 days. Furthermore, a CRI of more than 42 days was independently associated with higher DM (HR 1.89, 95% CI: 1.17-3.06; HR 1.96, 95% CI: 1.19-3.22), lower OS (HR 2.44, 95% CI: 1.41-4.35; HR 1.92, 95% CI: 1.10-3.33), and lower DFS (HR 1.84, 95% CI: 1.14-2.96; HR 1.82, 95% CI: 1.12-2.94) than a CRI of <28 or 28-42 days. However, SRI and CRI had no significant effect on LRR. CONCLUSIONS: Based on the present findings, the timing of the initiation of RT both after mastectomy and after the completion of adjuvant chemotherapy is crucial for patients with high-risk breast cancer.
引用
- Chen SY, Sun GY, Tang Y, et al. Timing of postmastectomy radiotherapy following adjuvant chemotherapy for high-risk breast cancer: A post hoc analysis of a randomised controlled clinical trial. Eur J Cancer. 2022. PMID: 35998550. doi:10.1016/j.ejca.2022.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。